Novartis Ends Bid to Block Imports of Regeneron’s Eye Syringes

Novartis’s efforts to block U.S. imports of Regeneron’s Eylea pre-filled syringes used to treat retinal diseases was dismissed after the company said it would pursue its patent-infringement claims in district court instead.

• The U.S. International Trade Commission terminated the case Monday based on a request filed by Novartis
  • Agency staff was recommending that no import ban be imposed for at least three years if Novartis won, citing concerns about public access to needed medicines
  • “Although Novartis disagrees with staff, it takes seriously the concerns staff noted,” the company said in its request to terminate the ITC investigation
• Novartis ...